Vera Therapeutics(NASDAQ) VERA

Vera helps people with serious immune system diseases that damage the kidneys. The company makes medicines that patients can give themselves at home using a simple injector. These treatments aim to stop the body from attacking its own healthy organs.

What Vera is Developing

• Atacicept: A protein-based medicine for kidney diseases like IgAN; designed for easy self-administration by patients at home.
• MAU868: An antibody treatment for BK virus infections; currently being tested for patients who have received organ transplants.
• VT-109: A new medicine in early development; focuses on blocking two specific proteins that cause immune system problems.

Milestones and Partnerships

• Submitted a formal application in November 2025 to the U.S. FDA for approval of its lead kidney medicine.
• Raised $281 million through a public stock sale in December 2025 to support its clinical research.
• Signed a major loan agreement in June 2025 with Oxford providing access to up to $500 million.
• Acquired the global rights to develop and sell the medicine candidate VT-109 in January 2025.
• Paid $15 million to Ares Trading S.A. in January 2026 after the FDA accepted its drug application for review.

The Strategy Behind the Science

The company uses a dual-inhibitor approach to block two specific signals in the immune system at once. This method aims to stop the body from producing harmful proteins that lead to kidney failure and other serious illnesses.

Key Financial Facts

• Net loss reached $121 million in Q1 2026, deepening 134% from $52 million in Q1 2025.
• Research and development spending hit $86 million in Q1 2026, up 108% from the previous year.
• General and administrative costs rose to $39 million in Q1 2026, up 146% year-over-year.
• Cash and marketable securities totaled $597 million as of March 31, 2026.
• Operating cash flow was negative $107 million in Q1 2026, worsening 96% from the prior year.

Evolution of the Business

Vera has moved from early research to the final stages of seeking regulatory approval for its first product. The company maintains a high-spending model to fund its pipeline of specialized immune system treatments.